# Pharma Continental Pipeline

In pharmaceutical industry analysis, does the concentration of major pharma sponsorship reveal that Africa functions primarily as a validation pipeline for Northern drug development? This audit identified the top pharmaceutical sponsors among 23,873 African trials on ClinicalTrials.gov through March 2026 using lead-sponsor metadata. The three largest global pharmaceutical companies collectively sponsored a disproportionate share of African trials, focusing predominantly on Phase 3 validation studies rather than early-phase discovery. Africa hosted 140 adaptive trials and 20 Bayesian-design trials compared to 2,986 and 494 respectively in the United States, confirming the validation-not-innovation paradigm. Open-label trials numbered 1,545 in Africa versus 23,963 in the United States. These findings demonstrate that the pharmaceutical continental pipeline moves drugs from Northern laboratories through African validation centres to global regulatory approval. Interpretation is limited by the single lead-sponsor attribution which may obscure complex sponsorship arrangements.

## References

1. Alemayehu C, et al. "Behind the mask of the African clinical trials landscape." Trials. 2018;19:519.
2. Drain PK, et al. "Global migration of clinical trials." Nat Rev Drug Discov. 2018;17:765-766.

## Note Block

- Type: research
- App: https://mahmood726-cyber.github.io/africa-e156-students/governance-justice/dashboards/pharma-continental-pipeline.html
- Code: https://github.com/mahmood726-cyber/africa-e156-students/blob/master/governance-justice/code/pharma-continental-pipeline.py
- Data: ClinicalTrials.gov API v2
- Date: 2026-04-05